GTx execs' sole drug fails the lead indication study in a painful setback -- shares smashed
GTx’s $GTXI big catalyst has blown up in their faces.
The Memphis-based biotech says that their Phase II ASTRID study comparing two doses of enobosarm for significantly reducing instances of stress urinary incontinence failed, which investors will not want to hear.
This was GTx’s lead indication on its one and only clinical-stage drug, and their stock imploded on the news, dropping more than 90% in an extinction-level event.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.